Usefulness of two independent DNA and rna tissue-based multiplex assays for the routine care of advanced NSCLC patients
Marin, Elba (Hospital Clínic i Provincial de Barcelona)
Teixidó, Cristina (Hospital Clínic i Provincial de Barcelona)
Carmona Rocha, Elena (Hospital Clínic i Provincial de Barcelona)
Reyes, Roxana (Hospital Clínic i Provincial de Barcelona)
Arcocha, Ainara (Hospital Clínic i Provincial de Barcelona)
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona)
Rodríguez-Mues, M Carmen (Hospital Clínic i Provincial de Barcelona)
Cabrera, Carlos (Instituto Oncologico Dr. Rosell)
Sánchez, Marcelo (Hospital Clínic i Provincial de Barcelona)
Vollmer, Ivan G. (Hospital Clínic i Provincial de Barcelona)
Castillo, Sergi (Hospital General de Granollers)
Muñoz, Silvia (Hospital General de Granollers)
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau)
Rodríguez, Adela (Hospital Clínic i Provincial de Barcelona)
Garcia, Mireia (Hospital Clínic i Provincial de Barcelona)
Alós, Silvia (Hospital Clínic i Provincial de Barcelona)
Jares, Pedro (Hospital Clínic i Provincial de Barcelona)
Martinez, Antonio (Hospital Clínic i Provincial de Barcelona)
Prat, Aleix (Hospital Clínic i Provincial de Barcelona)
Molina-Vila, Miguel Ángel (Quirón Dexeus University Hospital)
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Personalized medicine is nowadays a paradigm in lung cancer management, offering important benefits to patients. This study aimed to test the feasibility and utility of embedding two multiplexed genomic platforms as the routine workup of advanced non-squamous non-small cell lung cancer (NSCLC) patients. Two parallel multiplexed approaches were performed based on DNA sequencing and direct digital detection of RNA with nCounter® technology to evaluate gene mutations and fusions. The results were used to guide genotype-directed therapies and patient outcomes were collected. A total of 224 advanced non-squamous NSCLC patients were prospectively included in the study. Overall, 85% of samples were successfully characterized at DNA and RNA levels and oncogenic drivers were found in 68% of patients, with KRAS, EGFR, MET∆ex14, BRAF, and ALK being the most frequent (31%, 19%, 5%, 4%, and 4%, respectively). Among all patients with complete genotyping results and follow-up data (n = 156), the median overall survival (OS) was 1. 90 years (confidence interval (CI) 95% 1. 69-2. 10) for individuals harbouring an actionable driver treated with a matched therapy, compared with 0. 59 years (CI 95% 0. 39-0. 79) in those not eligible for any targeted therapy and 0. 61 years (CI 95% 0. 12-1. 10) in patients with no drivers identified (p < 0. 001). Integrating DNA and RNA multiplexing technologies into the routine molecular testing of advanced NSCLC patients is feasible and useful and highlights the necessity of widespread integrating comprehensive molecular diagnosis into lung cancer care.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Advanced non-small cell lung cancer ; Molecular diagnostics ; Oncogenic drivers ; Mutations ; Targeted therapies
Publicat a:	Cancers, Vol. 12 Núm. 5 (may 2020) , p. 1124, ISSN 2072-6694

DOI: 10.3390/cancers12051124
PMID: 32365867

14 p, 1.8 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats